Lemonn Mobile Sticky Banner

Nifty Jumps, Sensex Soars: Top Reasons Behind Today’s Market Move – 15th July 2026

Prefer us on Google — Button Prefer us on Google
Nifty 50 reclaimed 24,100 and Sensex rose over 450 points as IT, Biocon, crude prices, rupee and global cues shaped early trade.

Benchmark indices opened higher on Wednesday, with Nifty 50 climbing back above 24,100 and Sensex adding over 450 points in early trade, as firm Asian cues offset concerns over elevated crude prices and Middle East tensions.

The primary drivers were a rebound after Tuesday’s oil-led selloff, strength in select financials and pharma, and continued focus on IT stocks following global tech sector weakness.

Market Overview

Index15 Jul 2026 Opening / Early TradeMove & % ChangeComments
Nifty 50approx. 24,178.55+126 pts (+0.53%)Reclaimed 24,100 after prior session decline on crude spike.
BSE Sensexapprox. 77,514.53+460 pts (+0.60%)Opened firm, recovering from 561 point fall on Tuesday.
Gift Niftyapprox. 24,045+21 pts vs prev futuresIndicated flat to mildly positive start before cash market open.
  • Previous session, Sensex closed at 77,054.94, down 561.46 points.
  • Nifty 50 had settled at 24,052.05, down 158.95 points.
  • Tuesday’s decline was driven by Brent crude rising above 85 dollars per barrel.

Global Cues

Market/AssetMovementNotes
Dow Jones Industrial Averageapprox. +0.02%Supported by strong US bank earnings and softer inflation.
S&P 500approx. +0.38%Benefited from cooler US CPI and risk-on sentiment.
Nasdaq Compositeapprox. +0.90%Tech-led gains despite sector rotation concerns.
Nikkei 225approx. +0.89%Tracked Wall Street gains, AI and semiconductor optimism.
Kospiapprox. +6.75% to 7.04%Rally, region’s top performer despite Middle East tensions.
Hang Sengapprox. +1.31%Strength in Asian equities lifted sentiment.
Brent Crudeapprox. 85.82 dollars, up 1.29%Rising on renewed Middle East tensions and Strait of Hormuz risks.
WTI Crudeapprox. 80.17 dollars, up 1.05%Higher on supply disruption fears.
  • Softer US CPI at 3.5% year on year in June improved global risk appetite.
  • Expectations of a less aggressive US Federal Reserve stance aided equities.
  • Geopolitical tensions between the US and Iran kept crude and risk premia elevated.

Sectoral Action

Sector/IndexDirection (approx.)Key Drivers
ITmixed, focus after prior fallIBM-led global software weakness and HCLTech earnings weighed on sentiment.
Pharma / Biotechup, stock-specificBiocon in focus after Mylan exit block deal and divergent brokerage views.
EnergycautiousHigher crude prices raised concerns on margins and inflation.
FinancialsfirmGlobal bank earnings strength supported domestic financial sentiment.
  • Elevated crude prices kept energy and oil-sensitive sectors under scrutiny.
  • Broader markets and several sectoral indices had declined in the previous session.

Key Movers

Top Gainers

StockSectorNotable Factor
BioconPharma / BiotechRallied over 6% Tuesday after Mylan’s ₹1,839 crore block deal exit.
  • Biocon: Mylan sold its 5.64% stake at ₹400 per share via block deal.
  • Buyers included major domestic mutual funds, insurers and a global sovereign investor.

Top Losers / Stocks Under Pressure

StockSectorNotable Factor
HCLTechIT servicesFell over 4% Tuesday despite strong Q1 profit and record deal bookings.
Tata ElxsiIT / Design servicesQ1 net profit declined 23% even as revenue rose 2.8% QoQ to ₹1,021 crore.
TCSIT servicesDropped about 2.5% in prior session after IBM’s 25% plunge.
InfosysIT servicesSlipped nearly 2% Tuesday, tracking global software weakness.
WiproIT servicesDeclined over 1% in previous trade following IBM update.
Tech MahindraIT servicesLost more than 2% amid concerns on discretionary tech spending.
Persistent SystemsIT servicesFell up to 2% in midcap IT basket.
CoforgeIT servicesDeclined up to 2%, mirroring sector sentiment.
  • IBM’s preliminary Q2 revenue at 17.2 billion dollars missed forecasts of 17.9 billion dollars.
  • IBM’s adjusted EPS of 2.93 dollars trailed expectations of 3.02 dollars.
  • The 25% IBM share price fall wiped out about 70 billion dollars in market value.
  • IBM CEO Arvind Krishna flagged weakness in software and infrastructure businesses.
  • Spending shifted toward AI hardware, including servers, storage and memory chips.
  • Investors fear delayed software projects could hurt Indian IT exporters’ growth.

Technical Outlook

StatisticValue/ChangeContext
Nifty 50 supportapprox. 24,000Psychological level, break may extend decline to 23,800 to 23,900 zone.
Nifty 50 resistanceapprox. 24,200Immediate upside cap for the index in near term.
Infosys 20-day EMAapprox. ₹1,077.27Stock traded just below EMA, indicating short-term pressure.
Infosys S2 levelapprox. ₹1,122.30Latest price around ₹1,075 signalled trade below second support.
  • Infosys closed at ₹1,102.6 in previous session, down 0.88%.
  • Early trade price around ₹1,075, 1,077 showed continued weakness.
  • Infosys delivered -2.1% one-month and -14.4% three-month returns.

Currency And Macro Watch

StatisticValue/ChangeContext
Rupee vs US dollarapprox. ₹96.16 per dollarSlipped below 96, pressured by higher crude and foreign outflows.
  • Rupee weakness raises imported inflation risks given India’s crude import dependence.
  • Higher fuel costs can affect transportation, manufacturing and household budgets.
  • Forex participants cited safe-haven dollar demand and equity outflows.

Biocon: Divergent Brokerage Views

  • Bernstein retained Underperform on Biocon with ₹326 target, implying about 25% downside.
  • Bernstein said the block deal mainly gave Viatris a clean exit, limited earnings impact.
  • It noted slow revenue traction in Biologics and Syngene relative to leverage.
  • Policy changes may reduce biosimilar entry barriers, challenging Biocon’s advantages.
  • Bernstein expects Biocon may take four to five years to reach 2 billion dollars revenue.
  • DAM Capital maintained Buy with ₹495 target, citing overhang removal.
  • It noted other restructuring-linked investors may monetise holdings eventually.
  • DAM Capital sees Biocon’s biosimilars business at an inflection point.
  • It expects earnings momentum from H2 FY27 via products like bUstekinumab and bAspart.
  • Forecasts include 15% revenue CAGR between FY26 and FY28 and 26, 27% EBITDA margins.
  • “Market direction will continue to be driven by developments surrounding the Strait of Hormuz, movements in crude oil prices, and the ongoing earnings season”, said Ponmudi R, CEO, Enrich Money.

Frequently Asked Questions

Why did Nifty 50 and Sensex open higher on 15 July 2026?

Nifty 50 and Sensex opened higher as investors bought after Tuesday’s crude-led selloff, supported by firm Asian markets, strong US earnings and softer US inflation, even as Middle East tensions kept crude prices elevated.

What is driving weakness in Indian IT stocks currently?

Indian IT stocks are under pressure after IBM’s 25% plunge on weaker preliminary results and a shift in enterprise spending toward AI hardware, raising concerns about delayed software projects and subdued discretionary tech budgets for Indian exporters.

How are crude prices and the rupee impacting Indian equities?

Brent near 86 dollars and a rupee around 96.16 per dollar are heightening worries about imported inflation, higher fuel and input costs, and pressure on corporate margins, which in turn is influencing equity valuations and risk appetite.

Disclaimer

The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.

Sleek Sticky Registration Footer